These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Clinical Metabolomics to Segregate Aromatic Amino Acid Decarboxylase Deficiency From Drug-Induced Metabolite Elevations. Pappan KL; Kennedy AD; Magoulas PL; Hanchard NA; Sun Q; Elsea SH Pediatr Neurol; 2017 Oct; 75():66-72. PubMed ID: 28823629 [TBL] [Abstract][Full Text] [Related]
6. Assessment of renal dopaminergic system activity during cyclosporine A administration in the rat. Pestana M; Vieira-Coelho MA; Pinto-do-O PC; Fernandes MH; Soares-da-Silva P Br J Pharmacol; 1995 Aug; 115(8):1349-58. PubMed ID: 8564191 [TBL] [Abstract][Full Text] [Related]
7. Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. Wachtel SR; Bencsics C; Kang UJ J Neurochem; 1997 Nov; 69(5):2055-63. PubMed ID: 9349551 [TBL] [Abstract][Full Text] [Related]
8. Concerted action of dopamine on renal and intestinal Na(+)-K(+)-ATPase in the rat remnant kidney. Vieira-Coelho MA; Serrão P; Guimarães JT; Pestana M; Soares-da-Silva P Am J Physiol Renal Physiol; 2000 Dec; 279(6):F1033-44. PubMed ID: 11097621 [TBL] [Abstract][Full Text] [Related]
9. L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency? Jankovic J Ann Neurol; 1981 Jul; 10(1):64-5. PubMed ID: 7271235 [No Abstract] [Full Text] [Related]
12. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family. Maller A; Hyland K; Milstien S; Biaggioni I; Butler IJ J Child Neurol; 1997 Sep; 12(6):349-54. PubMed ID: 9309516 [TBL] [Abstract][Full Text] [Related]
13. Determination of some L-3,4-dihydroxyphenylalanine and dopamine metabolites in urine by means of mass fragmentography. Muskiet FA; Fremouw-Ottevangers DC; van der Meulen J; Wolthers BG; de Vries JA Clin Chem; 1978 Jan; 24(1):122-7. PubMed ID: 73430 [TBL] [Abstract][Full Text] [Related]
14. Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease. Pestana M; Jardim H; Serrão P; Soares-da-Silva P; Guerra L Kidney Blood Press Res; 1998; 21(1):59-65. PubMed ID: 9661138 [TBL] [Abstract][Full Text] [Related]
16. Conjugation of L-DOPA and its metabolites after oral and intravenous administration to Parkinsonian patients. Bronaugh RL; MacMurtry RJ; Hoehn MM; Rutledge CO Biochem Pharmacol; 1975 Jul; 24(13-14):1317-20. PubMed ID: 1096899 [No Abstract] [Full Text] [Related]
17. [Development in the metabolism of dopamine and its derivatives. Application to gross development disorders]. Martineau J; Garreau B; Barthélémy C; Jouve J; Lelord G Neurophysiol Clin; 1992 Jun; 22(2):179-89. PubMed ID: 1630417 [TBL] [Abstract][Full Text] [Related]
18. A study of endogenous dopamine metabolism in Gilles de la Tourette's disease. Messiha FS; Knopp W Dis Nerv Syst; 1976 Aug; 37(8):470-3. PubMed ID: 1066216 [TBL] [Abstract][Full Text] [Related]
19. Pyridoxal 5'-phosphate deficiency causes a loss of aromatic L-amino acid decarboxylase in patients and human neuroblastoma cells, implications for aromatic L-amino acid decarboxylase and vitamin B(6) deficiency states. Allen GF; Neergheen V; Oppenheim M; Fitzgerald JC; Footitt E; Hyland K; Clayton PT; Land JM; Heales SJ J Neurochem; 2010 Jul; 114(1):87-96. PubMed ID: 20403077 [TBL] [Abstract][Full Text] [Related]
20. Urinary dopamine in aromatic L-amino acid decarboxylase deficiency: the unsolved paradox. Wassenberg T; Willemsen MA; Geurtz PB; Lammens M; Verrijp K; Wilmer M; Lee WT; Wevers RA; Verbeek MM Mol Genet Metab; 2010 Dec; 101(4):349-56. PubMed ID: 20832343 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]